89bio Inc Stock Buy Hold or Sell Recommendation
| ETNB Stock | USD 8.88 0.28 3.06% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding 89bio Inc is 'Hold'. Macroaxis provides 89bio buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding 89bio positions. The advice algorithm takes into account all of 89bio's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting 89bio's buy or sell advice are summarized below:
Real Value 15.19 | Target Price 33.44 | Hype Value 9 | Market Value 8.88 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell 89bio Inc given historical horizon and risk tolerance towards 89bio. When Macroaxis issues a 'buy' or 'sell' recommendation for 89bio Inc, the advice is generated through an automated system that utilizes algorithms and statistical models.
89bio |
Execute 89bio Buy or Sell Advice
The 89bio recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on 89bio Inc. Macroaxis does not own or have any residual interests in 89bio Inc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute 89bio's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
89bio Trading Alerts and Improvement Suggestions
| 89bio Inc generated a negative expected return over the last 90 days | |
| 89bio Inc has high historical volatility and very poor performance | |
| Net Loss for the year was (142.19 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| 89bio Inc currently holds about 193.34 M in cash with (129.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.16. | |
| 89bio Inc has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: 89bio Enhances Board with Biopharma Veteran Martin Babler - TipRanks.com - TipRanks |
89bio Returns Distribution Density
The distribution of 89bio's historical returns is an attempt to chart the uncertainty of 89bio's future price movements. The chart of the probability distribution of 89bio daily returns describes the distribution of returns around its average expected value. We use 89bio Inc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of 89bio returns is essential to provide solid investment advice for 89bio.
| Mean Return | -0.16 | Value At Risk | -6.8 | Potential Upside | 9.11 | Standard Deviation | 5.00 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of 89bio historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
89bio Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as 89bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading 89bio Inc backward and forwards among themselves. 89bio's institutional investor refers to the entity that pools money to purchase 89bio's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bvf Inc | 2023-09-30 | 1.8 M | Westfield Capital Management Company, Lp | 2023-12-31 | 1.8 M | Braidwell Lp | 2023-09-30 | 1.6 M | Citadel Advisors Llc | 2023-09-30 | 1.5 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.5 M | Geode Capital Management, Llc | 2023-12-31 | 1.4 M | Goldman Sachs Group Inc | 2023-12-31 | 1.3 M | Octagon Capital Advisors Lp | 2023-09-30 | 1.2 M | Laurion Capital Management Lp | 2023-09-30 | 1.2 M | Ra Capital Management, Llc | 2023-12-31 | 11.4 M | Hhg Plc | 2023-12-31 | 8.9 M |
89bio Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (139K) | (106.8M) | 7.2M | 118.8M | (70.4M) | (66.9M) | |
| Change In Cash | 82.1M | 4.8M | (45.8M) | 2.8M | 260.9M | 274.0M | |
| Free Cash Flow | (25.6M) | (46.4M) | (76.8M) | (81.1M) | (129.2M) | (122.7M) | |
| Depreciation | 17K | 60K | 79K | 65K | 273K | 286.7K | |
| Other Non Cash Items | 30.6M | 498K | 1.5M | (41K) | (4.2M) | (4.0M) | |
| Capital Expenditures | 139K | 126K | 63K | 7K | 4K | 3.8K | |
| Net Income | (57.4M) | (49.5M) | (90.1M) | (102.0M) | (142.2M) | (135.1M) | |
| End Period Cash Flow | 93.4M | 98.2M | 52.5M | 55.3M | 316.2M | 332.0M | |
| Change To Netincome | 31.0M | 4.0M | 9.4M | 10.4M | 9.3M | 8.9M |
89bio Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to 89bio or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that 89bio's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a 89bio stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.28 | |
β | Beta against NYSE Composite | 2.39 | |
σ | Overall volatility | 5.11 | |
Ir | Information ratio | -0.04 |
89bio Volatility Alert
89bio Inc exhibits very low volatility with skewness of -0.43 and kurtosis of 2.21. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure 89bio's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact 89bio's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.89bio Fundamentals Vs Peers
Comparing 89bio's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze 89bio's direct or indirect competition across all of the common fundamentals between 89bio and the related equities. This way, we can detect undervalued stocks with similar characteristics as 89bio or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of 89bio's fundamental indicators could also be used in its relative valuation, which is a method of valuing 89bio by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare 89bio to competition |
| Fundamentals | 89bio | Peer Average |
| Return On Equity | -0.41 | -0.31 |
| Return On Asset | -0.24 | -0.14 |
| Current Valuation | 324.34 M | 16.62 B |
| Shares Outstanding | 93.5 M | 571.82 M |
| Shares Owned By Insiders | 0.85 % | 10.09 % |
| Shares Owned By Institutions | 99.15 % | 39.21 % |
| Number Of Shares Shorted | 11.55 M | 4.71 M |
| Price To Earning | (1.04) X | 28.72 X |
| Price To Book | 1.71 X | 9.51 X |
| EBITDA | (150.93 M) | 3.9 B |
| Net Income | (142.19 M) | 570.98 M |
| Cash And Equivalents | 193.34 M | 2.7 B |
| Cash Per Share | 4.16 X | 5.01 X |
| Total Debt | 27.11 M | 5.32 B |
| Debt To Equity | 0.13 % | 48.70 % |
| Current Ratio | 5.81 X | 2.16 X |
| Book Value Per Share | 5.75 X | 1.93 K |
| Cash Flow From Operations | (129.19 M) | 971.22 M |
| Short Ratio | 7.20 X | 4.00 X |
| Earnings Per Share | (2.00) X | 3.12 X |
| Price To Earnings To Growth | (0.45) X | 4.89 X |
| Target Price | 31.89 | |
| Number Of Employees | 70 | 18.84 K |
| Beta | 0.95 | -0.15 |
| Market Capitalization | 876.11 M | 19.03 B |
| Total Asset | 596.27 M | 29.47 B |
| Retained Earnings | (457.43 M) | 9.33 B |
| Working Capital | 563.92 M | 1.48 B |
| Current Asset | 10.12 M | 9.34 B |
| Current Liabilities | 3.89 M | 7.9 B |
| Net Asset | 596.27 M |
Note: Disposition of 15000 shares by Rohan Palekar of 89bio at 20.0 subject to Rule 16b-3 [view details]
89bio Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as 89bio . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About 89bio Buy or Sell Advice
When is the right time to buy or sell 89bio Inc? Buying financial instruments such as 89bio Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 10.2M | 11.9M | 20.5M | 10.3M | Total Assets | 162.4M | 196.8M | 596.3M | 626.1M |
Use Investing Ideas to Build Portfolios
In addition to having 89bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Power Assets Thematic Idea Now
Power Assets
Large capitalization equities showing high long-term performance indicators and above average return expectations based on Macroaxis rating system. The Power Assets theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Power Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Check out 89bio Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for 89bio Stock analysis
When running 89bio's price analysis, check to measure 89bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 89bio is operating at the current time. Most of 89bio's value examination focuses on studying past and present price action to predict the probability of 89bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 89bio's price. Additionally, you may evaluate how the addition of 89bio to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is 89bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 89bio. If investors know 89bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 89bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.00) | Return On Assets (0.24) | Return On Equity (0.41) |
The market value of 89bio Inc is measured differently than its book value, which is the value of 89bio that is recorded on the company's balance sheet. Investors also form their own opinion of 89bio's value that differs from its market value or its book value, called intrinsic value, which is 89bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 89bio's market value can be influenced by many factors that don't directly affect 89bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 89bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if 89bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 89bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.